# Experimental immune therapy shows promise against deadly childhood brain cancer A new treatment method has shown successful results in children with recurrent brain tumors. - **Source:** [Scientific American Content: Global](https://brifing.si/source/4f066134-e06d-4415-87ef-305e3dc2aba6) - **Published:** 2026-07-14 - **Original article:** - **On Brifing:** https://brifing.si/s/54220551-1309-498f-a132-b44901b58faa ## Childhood brain cancer Brain and spinal cord tumors are among the most deadly cancers in children. Current treatments often offer limited options and present a challenging process for families. ## Experimental T cell therapy A new immune therapy uses the patient's own T cells to target brain tumors. This treatment shows promise, especially for recurrent tumors. ## Clinical trial results In an early-stage clinical trial, three children who received the treatment showed no signs of cancer. These children had not responded to years of chemotherapy and radiation. ## How the treatment works The treatment involves multiplying T cells taken from the patient's blood in a lab and reintroducing them to the patient. These cells recognize proteins in the tumor and activate the immune system. ## Challenges in brain cancer Completely removing brain tumors can damage areas controlling vital functions. Additionally, the blood-brain barrier prevents drugs from reaching tumors in effective doses. ## Hope for the future Although this treatment is in its early stages, it could improve survival rates for children. Larger clinical trials are needed to confirm its effectiveness. ## Sources covering this story - https://www.scientificamerican.com/article/experimental-immune-therapy-shows-promise-against-deadly-childhood-brain-cancer/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._